This is an important advancement in modeling disease mechanisms in the laboratory as, up until this point, transgenic models have focused mainly on genes related to early onset AD, such as APP and presenilin mutations, which represent only a small fraction of human AD patients. The gene discussed is APP; the disease is Alzheimer disease.